Piper Sandler Maintains Overweight on Health Catalyst, Lowers Price Target to $11
Piper Sandler Maintains Overweight on Health Catalyst, Lowers Price Target to $11
派傑投資維持對health catalyst的超額評級，將目標價下調至11美元。
Piper Sandler analyst Jessica Tassan maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from $14 to $11.
派傑投資分析師Jessica Tassan 維持health catalyst（納斯達克：HCAT）評級爲超重，將目標價格從14美元下調至11美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。